Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications

K F Yoong, D H Adams

Introduction
Although the interaction between the host immune system and cancer cells is still not fully understood certain clinical and experimental observations suggest that T cell mechanisms play an important role in anti-tumour immunity. In the clinical setting, spontaneous regression of some cases of malignant melanoma has been reported and these tumours are heavily infiltrated by lymphocytes. Furthermore, certain solid tumours which contain a high number of lymphocytes are associated with a better prognosis than those with less intense lymphocytic infiltration. The increased incidence of many solid tumours in immunosuppressed hosts also supports the importance of roles of cellular immunity in host defence against tumour growth. More recent studies of T cell receptor (TCR) α and β variable gene expression have shown that T cells infiltrating solid tumours are clonally expanded, suggesting that they have recognised antigens in the tumour environment, thus providing further evidence for the specificity of the anti-tumour response. Recent advances in cellular and molecular immunology have provided important insights into the complex mechanisms that regulate the immune response to tumours and have led to potentially exciting developments in cancer treatment. In this article we shall review the role of tumour infiltrating lymphocytes in the immune response against solid organ tumours and discuss the potential for their use in adoptive immunotherapy of cancer.

From LAK cells to cytokine activated TIL
In 1976, interleukin-2 (IL-2) was shown to regulate the immune response by mediating the proliferation of antigen stimulated T lymphocyte clones through both autocrine and paracrine loops. The incubation of peripheral blood lymphocytes (PBL) or splenocytes with recombinant IL-2 generated effector cells which were capable of recognising and lysing autologous and allogeneic tumour cells in a non-MHC restricted fashion. These lymphokine activated killer (LAK) cells were used as anti-tumour effector cells in adoptive immunotherapy and showed promise in several animal studies, but only limited response rates were obtained in clinical studies. Furthermore, the therapeutic efficacy of LAK cells was dependent on concomitant administration of high doses of recombinant IL-2, which was poorly tolerated and often associated with serious toxicity related to increased capillary permeability and haemodynamic instability. In 1986, recombinant IL-2 was used to activate and expand lymphocytes from tumour tissue, tumour infiltrating lymphocytes (TIL), in the hope that these cells would show more potent and specific anti-tumour activity. This review article highlights the important developments in TIL research that have taken place in recent years, particularly with regard to the molecular mechanisms that underlie their anti-tumour activity and to evaluate the therapeutic potential of TIL.

TIL are potent anti-tumour effector cells in animal models
TIL are a heterogeneous population of mononuclear cells comprising mainly CD3+ T lymphocytes and, to a lesser degree, natural killer cells (NK) found in most solid tumour tissues (figs 1 and 2). TIL isolated from animal tumour models such as methylcholanthrene induced murine sarcoma are predominantly CD8+, and following a period of culture in high concentration of exogenous IL-2, they acquire the ability to lyse specifically autologous tumour, but not normal, cells. In addition, they release specific cytokines such as interferon-γ (INF-γ) and tumour necrosis factor-α (TNF-α) when challenged with autologous tumour cells. These studies suggest that murine TIL recognise and respond to specific tumour antigens. Subsequent in vivo studies showed that adoptively transferred TIL were effective in eradicating established three-day lung and liver micrometastases in murine sarcoma models and advanced tumours when used in conjunction with IL-2 and cyclophosphamide. In animal models, TIL seem to offer several therapeutic advantages over LAK cells; they are up to 100 times more potent as specific anti-tumour effector cells and could mediate the regression of LAK resistant tumours without the need for simultaneous administration of IL-2.

Isolation of TIL from human tumours
The impressive results from murine adoptive immunotherapy models provided the rationale for characterising human TIL with a view to utilising their anti-tumour activity in adoptive immunotherapy in humans. TIL have been isolated from a variety of human solid tumours including malignant melanoma, renal cell carcinoma, ovarian malignancies, colonic tumours, breast carcinoma, and lung cancer.
functional reactivity as well as continued growth. Some investigators found that periodic stimulation of TIL cultures with autologous tumour antigen enhanced long term growth and cytotoxic reactivity. In contrast, others have managed to expand TIL to therapeutic numbers without further restimulation with tumour antigens.

Characteristics of freshly isolated TIL

LINEAGE MARKERS ON HUMAN TIL

Phenotypic analysis by flow cytometry has demonstrated consistently that TIL derived from animal and human tumours comprise mainly CD3+ T cells and a variable proportion of CD3−CD56+ NK cells. However, there are differences in the composition of CD3+ subsets. TIL from animal tumour models are almost exclusively CD8+, whereas those from humans show a heterogeneous phenotypic profile with varying ratios of CD4+ and CD8+ cells. A preponderance of CD8+ T lymphocytes with a low CD4:CD8 ratio has been observed in fresh TIL isolated from metastatic melanoma, renal cell carcinoma, breast carcinoma, primary and secondary liver tumours, and squamous cell carcinoma of the head and neck. In contrast, TIL from colonic and ovarian tumours were found to be enriched in CD4+ T cells. Large granular lymphocytes expressing the CD56 antigen are usually found in small numbers in most fresh TIL populations.

ACTIVATION MARKERS

When compared with PBL, TIL show increased expression of several activation markers. A significant proportion of TIL derived from melanoma, renal cell, ovarian, and liver tumours express CD25, HLA-DR, CD45RO, and CD69 indicating that they have been activated in vivo, presumably by encounter with specific tumour antigens.

ADHESION MOLECULES

Cell adhesion molecules (CAMs) play a crucial role in the interaction between immune and tumour cells. CAMs on tumour cells regulate their interactions with endothelium and extracellular matrix and determine their ability to metastasise. Moreover, many of the CAMs that determine tumour metastasis can be induced or upregulated by cytokines secreted by activated monocytes and lymphocytes via interactions with cytokine receptors on the tumour cells. This raises the possibility that the presence of mononuclear cell infiltrates in some tumours might, paradoxically, benefit tumour survival by promoting metastasis. This might be particularly true of breast cancer, which is the only cancer reported to have a lower incidence in immunosuppressed patients.

In addition to their role in tumour metastasis CAMs play a crucial role in the recruitment of TIL to tumours and in their subsequent interactions with tumour cells. Lymphocyte recruitment to tissue involves sequential adhesive interactions between circulating lymphocytes and the endothelium. Initially, primary adhe-
We have important TIL homing used low Preliminary important express from those involved neck have recently been demonstrated that anti-cancer TILs may have a role in the treatment of cancer. In vitro studies have shown that freshly isolated TILs can effectively kill cancer cells, indicating that they are capable of killing cells expressing antigens specific to the patient's tumour. Furthermore, TILs are shown to secrete cytokines such as interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α), which are known to have an anti-inflammatory effect. In vivo, TILs have been shown to suppress tumour growth in a variety of experimental models, including mice and humans.

TILs are functionally deficient in their ability to proliferate to tumour antigens in vitro

There is substantial evidence to indicate that freshly isolated TILs are functionally deficient in terms of their capacity to proliferate, to release cytokines and to mediate anti-tumour cytotoxicity. Several hypotheses have been proposed to account for the impaired effector functions of fresh TIL. They include suggestions that tumours contain suppressor lymphocytes or that the tumour itself suppresses TIL cytokine release. There are conflicting data regarding the role of lymphoid suppressor cells in diminishing the proliferative capacity of TIL. Several studies detected the presence of lymphoid suppressor activity in patients with cancer of the lymphoid and breast cancer of the mucinous type had high expression of mRNA transcripts for TNF-α, IL-2 and IFN-γ, the non-mucin secreting breast tumour and ovarian carcinoma had absent or low levels of expression. Using RT-PCR, Gingras et al. reported decreased expression of mRNA for IL-2, IL-4, IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF), and IFN-γ in TIL freshly isolated from lung cancers and glioblastomas in comparison with activated autologous PBL. Numerous in vitro studies have been carried out to investigate the ability of TIL to release cytokines in vitro in response to autologous tumour challenge. The results are conflicting. For instance, whereas one group suggested that TIL derived from melanoma or breast cancers secreted GM-CSF, TNF-α and IFN-γ when co-cultured with autologous tumour cells, Guillox et al. reported that CD4+ and CD8+ T cells derived from melanoma did not produce large amounts of IL-2, IL-4 or IFN-γ when stimulated by autologous tumour cells. The recent extension of the T helper 1 (Th1) and Th2 paradigm of functional CD4 subsets into the CD8 lineage suggests that complex subsets of functionally distinct T cells may be present within tumours. However, whether these subsets develop as a consequence of the aberrant lymphocyte activation, or whether their functional activity determines it, is unclear at the moment.

There is evidence that an intrinsic lymphocyte defect in the antigen dependent activation pathway may be responsible for the impaired effector functions often seen in fresh TIL. Limiting dilution analysis showed a reduction in the frequency of proliferative T cell precursors which could not be reversed by the addition of autologous tumour cells. Miescher et al. found that fresh TIL in low density culture did not proliferate in response to stimulation by low dose IL-2, mitogens such as phytohaemagglutinin, or cross linking the TCR with anti-CD3 monoclonal antibody. TIL show defective tumour cytotoxicity in vitro

T cell cytotoxicity is mediated by at least two distinct mechanisms: namely, perforin dependent induction of membrane lysis and Fas induced DNA fragmentation and apoptosis. Fas (APO-1, CD95) is a cell surface molecule that can mediate both apoptotic cell death of transformed cells and co-stimulatory signal transduction. It has been proposed that signalling through Fas upregulates the early
Table 1 Abnormalities of T cell signal transduction in malignancy

<table>
<thead>
<tr>
<th>Tumour type</th>
<th>Signalling defect</th>
<th>Source of T cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>Murine colonic and renal carcinoma</td>
<td>Reduced level of CD3ζ, p56κκ and p59αα</td>
<td>Spleen</td>
</tr>
<tr>
<td>Murine fibrosarcoma</td>
<td>Reduced level of CD3ζ, p56κκ and p59αα</td>
<td>Spleen</td>
</tr>
<tr>
<td>Human renal cell carcinoma</td>
<td>Reduced level of CD3ζ and p56κκ</td>
<td>TIL</td>
</tr>
<tr>
<td>Human colorectal carcinoma</td>
<td>Reduced level of CD3ζ</td>
<td>TIL and NK cells</td>
</tr>
<tr>
<td>Human renal cell, hepatic metastases and head and neck carcinomas</td>
<td>Reduced level of CD3ζ</td>
<td>PBL</td>
</tr>
<tr>
<td>Human renal cell carcinoma</td>
<td>NF-κB/Rel family of transcription factors</td>
<td>Spleen</td>
</tr>
<tr>
<td>Human renal cell carcinoma</td>
<td>Abnormal NF-κB specific DNA binding activity</td>
<td>TIL and PBL</td>
</tr>
</tbody>
</table>

Figure 3 Cytotoxic activities of fresh (uncultured) TIL isolated from a hepatocellular carcinoma and assessed by a four hour chromium release assay against autologous, K562 and Daudi targets.

Defects of signal transduction in T cells of tumour bearing hosts

A better understanding of the molecular mechanisms regulating T cell induction, especially the mechanisms of signal transduction by the TCR, has provided an insight into the nature of the functional defects often seen in fresh TIL. In general, cytotoxic T lymphocytes (CTL) utilise the TCR/CD3 complex to recognise antigenic peptides presented in conjunction with MHC molecules. Several studies have described major abnormalities in the structure of the TCR-CD3 complex and its associated signal transduction pathways in T cells of tumour bearing hosts (Table 1). Splenocytes from mice bearing MCA-38 colonic carcinoma for a duration of more than 28 days showed absent or reduced expression of CD3ζ, p56κκ, p59αα and a decreased ability to mobilise intracellular Ca²⁺ in response to activation signals. The absent expression of CD3ζ was associated with increased levels of the Fc-ε chain. These changes were detected on both CD4+ and CD8+ T cells from tumour bearing mice but not in splenic T cells obtained from mice exposed to the same tumour for shorter durations. CD3ζ and p56κκ are important elements of the signal transduction mechanism for the TCR-CD3 complex. In addition, these signalling abnormalities were associated with reduced in vivo antitumour activity and in vitro effector functions of T cells isolated from tumour bearing hosts. Similar findings were reported in T cells derived from patients with renal cell and colorectal cancers, and the altered expression of CD3ζ and p56κκ were more pronounced in TIL than in autologous PBL. Compared with PBL from healthy controls, those from patients with colorectal hepatic metastases and squamous cell carcinoma of the head and neck were also found to have reduced levels of CD3ζ. It is not known whether the diminished CD3ζ expression is unique to malignant diseases or is also seen in other conditions characterised by immune deficiency. More recent studies have described abnormalities of the NF-κB/Rel family of transcription factors in T cells of tumour bearing mice and patients with renal carcinoma, suggesting that the signalling mechanisms regulating gene transcription might be defective in tumour bearing hosts.

TCR/peptide-MHC engagement is not in itself sufficient for complete activation of T cells. An additional co-stimulatory signal is required to sustain the TCR mediated activation pathway and to prevent the induction of anergy. It is therefore possible that defective costimulation of TIL might be responsible for their functional deficiencies. Certain cellular adhesion molecules that can provide this second activation signal include CD28, CD11a/CD18 and CD2 on T cells and their respective ligands B7-1 and B7-2, ICAM-1, -2 and -3, and LFA-3 on antigen presenting cells. The CD28/B7 pathway is particularly important for preventing the induction of anergy and the absence of B7 expression in some tumours has been proposed as a mechanism for the incomplete activation of T cells and the subsequent failure of the host immune system to mount an effective anti-tumour response in vivo. These observations have led to studies in which tumour cells are transfected with B7-1 to enhance their immunogenicity. Such studies have been successful in animals but so far have not been extended to clinical trials.
A recent study reported an absence of transferrin receptor (TfR) expression associated with low levels of mRNA transcripts in TIL derived from renal cell carcinoma. As the uptake of transferrin is essential for initiating T cell proliferation, the failure to express TfR may be another intrinsic defect of TIL that might explain their diminished proliferative capacity compared with PBL.

Although the nature and source of the factors responsible for inducing these functional deficits in TIL are not known, the available evidence suggests that they are related to the local tumour environment. Further support for this hypothesis comes from the identification of tumour-derived factors including soluble secreted factors, such as cytokine transforming growth factor-β, prostaglandins, p15E retrovirus-related glycoprotein, and cell surface gangliosides that are capable of suppressing host immune function.

**TCR V gene expression in human TIL**

Analysis of TCR V gene usage by T cells infiltrating tumours has been used to detect tumour specific immune responses in vivo. This is based on the assumption that accumulations of T cells that recognise and respond to tumour-associated antigens will display a restricted pattern of TCR V gene expression. Quantitative RT-PCR is used to determine the percentage gene expression of each Vα and Vβ region and a ratio of greater than 1.8–2.0 when compared with autologous PBL is considered to be significant. When autologous PBL are not available, values outside the mean +2 SD established for each Vα and Vβ region using PBL of normal controls are deemed to indicate significant overexpression of the corresponding gene. Nitta et al were the first group to report the preferential expression of Vα7 in fresh TIL of primary uveal melanomas and subsequent studies by the same group described oligoclonal T cells with a restricted Vα and Vβ TCR repertoire infiltrating other primary melanomas, medulloblastomas and gliomas. More recent studies have used quantitative techniques to confirm the restricted TCR gene expression in a variety of tumours, including primary and metastatic melanomas, basal cell carcinoma, squamous cell carcinoma of the head and neck, hepatocellular carcinoma, renal cell carcinoma, ovarian cancer, and gliomas. Although a restricted TCR repertoire has been found in many tumours, the restriction pattern varied between patients with the same type of tumour, suggesting either that TIL from different patients recognised and responded to different tumour antigens or that the same tumour-associated antigen can be presented in different ways by MHC. In the majority of the early studies, neither the relevant antigenic epitope nor the MHC restricting element was known. Subsequent studies carried out on patients with melanoma matched for HLA-A2 found that Vβ14 was expressed preferentially in all of the tumours studied. Vβ14 overexpression was not detected in melanomas of HLA-A2 negative patients and was tumour specific as it was not found in autologous normal skin. The interpretation of TCR analysis on T cells infiltrating tumour tissue has to take into account that comparison with normal autologous tissue is important as several studies have shown that preferential expression of certain V gene groups occur in specific tissues, such as the skin and the gut. Furthermore, variations in Vα and Vβ subfamilies have been reported in primary and secondary lesions of the same patient and differences were also observed in metastases that developed during tumour progression. This may be explained by a change in tumour phenotype with respect to loss of HLA class I expression or loss of antigenic epitope that has been observed in the progression of some tumours.

The demonstration of restricted TCR expression in tumours does not provide direct evidence to correlate certain TCR subfamilies with tumour specific T cell responses. The functional significance of restricted TCR expression in TIL was investigated by Mackensen et al who generated HLA-B14 restricted T cell clones with tumour specific cytotoxicity from a regressing melanoma lesion. That the Vβ16 gene was highly expressed in both the in vitro T cell clone and the in situ TIL suggested that clonal T cells bearing this particular TCR were responsible for mediating tumour regression in this instance. Another group have also demonstrated the same restricted TCR expression in tumour specific T cell clones and in fresh TIL of a patient with melanoma. Together these studies suggest strongly that the accumulation of clonal T cells in melanomas occurs and in some cases, may play an important role in tumour specific immunity.

**The role of CD4+ T cells in anti-tumour response**

Recent evidence obtained from animal studies suggests that CD4+ T cells are just as important CD8+ T cells in the development of a successful anti-tumour immune response. Activated CD4+ T cells can be classified into two functional types based on their profile of cytokine production. Th1 cells produce IL-2, IFN-γ and TNF-α, and a functional consequence of their activation is the promotion of a cellular immune response that is associated with IgG2a production and macrophage activation. Th2 cells are characterised by IL-4, IL-5, IL-6, IL-10, and IL-13 production and the development of selected humoral responses associated with IgG1 and IgE expression, and eosinophil and mast cell activation. T cell clones producing various combinations of Th1 and Th2 cytokines are designated ThO. A functional consequence of the cytokines secreted by one subset is the suppression of activity in the other subset. There is evidence that these cytokines have important roles in mediating anti-tumour immune responses by regulating the induction and effector mechanisms of immune cells. In some animal tumour models, the Th1 cytokine profile is associated...
with complete tumour regression and a successful recall response to subsequent tumour challenge. Conversely, Ghosh et al. demonstrated that splenic T cells from renal cell cancer bearing mice lose the Th1 phenotype with progressive tumour growth and reverted to the Th1 phenotype when successfully treated with IL-2 and flavone 8-acetic acid.

IL-12 is a recently described cytokine which has wide ranging immunoregulatory activities, such as augmenting the cytokytic capacity of and production of IFN-γ by activated NK and T cells and inducing the differentiation of naive Th cells to the Th1 phenotype. The role of IL-12 in mediating tumour regression in vivo was investigated recently by Fallarino et al. in a series of experiments using P1.HTR and P198 tumour models which are normally rejected by 33% and 100% of mice, respectively. The neutralisation of endogenous IL-12 by antiserum inhibited the production of IFN-γ by T cells isolated from lymph nodes of P1.HTR tumour bearing mice and prevented tumour rejection. In another group of mice bearing P198, a highly immunogenic tumour variant which is normally rejected by the majority of inoculated mice, tumour progression was observed in all mice treated with anti-IL-12. Further support for the protective role of IL-12 was provided by the observations that the administration of exogenous IL-12 following tumour inoculation resulted in more than 90% of mice rejecting the P1.HTR tumour.

**Functional characteristics of cytokine modulated TIL.**

The functional deficiencies of freshly isolated TIL can be reversed by the presence of high concentrations (6000 IU/ml) of IL-2 in the culture medium (fig 4). This encourages the selective outgrowth of CD25+ lymphocyte subsets with enhanced proliferative and anti-tumour cytotoxic properties. The use of high concentrations of exogenous IL-2 tends to generate effector cells with a broad spectrum of cytotoxicity. Using cell sorting techniques on TIL derived from squamous cell carcinoma of the head and neck and ovarian tumours cultured in high doses of IL-2, Heo et al. found that the effector cells responsible for cytotoxicity were CD3+CD56+ NK cells and CD3+CD56+ MHC unrestricted T cells. Thus, activation of TIL in vitro with high concentrations of IL-2 tends to generate non-specific anti-tumour effectors with similar phenotype and cytotoxic characteristics to LAK cells. Topalian et al. reported two important observations regarding effector phenotype and the nature of anti-tumour cytotoxicity in melanoma TIL: that cytotoxicity against allogeneic targets was mediated mainly by CD56+ cells while lysis of specific autologous tumour cells was mediated by a subpopulation of cells with the CD3+CD8+ phenotype. CD8+ CTL have been generated consistently from melanoma TIL, but less frequently from other tumours. Tagaki et al. reported CD4+ mediated tumour specific effector function in TIL derived from primary liver tumours. However, TIL from other tumours tend to display non-specific anti-tumour activity mediated by a combination of CD3−CD56+ NK cells and CD3+CD56+ MHC unrestricted T cells (ovarian, colorectal and renal cell carcinoma). The nature of effector cells generated from TIL will depend not only on the characteristics of the TIL in vivo but also on the particular phenotypes that are encouraged to grow by the in vitro culture conditions. It is therefore important to analyse carefully the TIL generated by a particular culture protocol as this will determine the phenotype and hence the function of the cultured cells. Various studies have demonstrated that tumour specific CTL against ovarian, a liver metastasis of gastric cancer and renal cell carcinoma could be expanded more consistently by low doses (100–600 IU/ml) of IL-2. Thus, sufficient IL-2 should be used to overcome the failure of TIL proliferation but the use of excessive IL-2 should be avoided as this results in a loss of specificity in the TIL generated. A variety of other cytokines have been used to activate TIL with the aim of defining optimal in vitro conditions for selecting the outgrowth and expansion of CD8+ CTL. The use of IL-4, IL-6 or IL-7 in conjunction with IL-2 was reported to enhance the proliferative capacity of TIL derived from renal cell carcinoma but not change their cytotoxic characteristics. The combination of IL-2 and IL-4 or IL-6 has been shown to augment the expansion of TIL specific for autologous melanoma. In primary liver tumours a combination of TNF-α and IL-2 was more effective than IL-2 alone in generating CD8+ effectors with enhanced cytotoxicity against autologous tumour cells, but greatly reduced activity against allogeneic, K562 and Daudi targets. Furthermore, the addition of IFN-γ to TNF-α plus IL-2 resulted in enhanced cytotoxicity for both autologous and
### TIL recognition of tumour associated antigens

T lymphocytes utilise the TCR/CD3 complex to recognise foreign antigens in association with MHC (in man the human leucocyte antigens or HLA). Class I MHC antigens (HLA-A, B and C) are found in all nucleated cells and serve as target structures predominantly for CD8+ T cells when modified by endogenously processed foreign proteins. Class II antigens (HLA-DP, DR and DQ) are presented on activated lymphocytes and antigen presenting cells, including B cells, dendritic cells and monocyte/macrophage cells. They present exogenous antigen that has been processed by antigen presenting cells predominantly to CD4+ T cells.

Most antigens recognised by T lymphocytes are short peptides (9–14 amino acids) bound to MHC molecules. These peptides are produced by the degradation of proteins inside the antigen presenting cell, 114 T cells which recognise and respond to tumour cells in an MHC restricted manner have been generated from either TIL or PBL of patients with melanoma. 115 129 120 squamous cell carcinoma of the head and neck, 121 liver metastasis of a gastric carcinoma, 110 and ovarian tumours. 109 The demonstration that the specific reactivity of CTL can be inhibited by monoclonal antibodies against the TCR and MHC molecules provides strong evidence that recognition of tumour cells is both TCR mediated and MHC restricted. The search for MHC associated peptides that are selectively expressed on tumour cells and that act as epitopes for tumour specific CTL is an area of intense current interest because of the exciting potential of therapeutic anti-tumour vaccination. Melanoma associated peptide epitopes encoded by MAGE-1, 122 MAGE-3, 123 tyrosinase, 124 125 gp100, 126 127 MART-1, 128 and gp75 131 have been identified (table 2). The first peptide epitope for a human tumour was identified by Van der Bruggen et al. 152 using CTL clones to screen transfected cDNA libraries. A gene identified as MAGE-1 encodes the tumour antigen MZ2-E in association with HLA-A1 on a human melanoma cell line. This gene is expressed in 20–40% of tumours of several different histological types, including melanoma, breast cancer, non-small cell lung cancer, squamous cell carcinoma of the head and neck, and bladder cancer. 132 The same group identified a second gene, MAGE-3, that encodes a HLA-A1 restricted peptide epitope recognised by autologous CTL from a patient with melanoma. 133 The peptides encoded both by MAGE-1 and -3 are highly homologous and are not expressed in normal tissues except the human testis.

Other peptide epitopes on human melanoma cells are products of genes expressed in a tissue specific, rather than a tumour specific, manner and are restricted by HLA-A2. Tyrosinase is a transmembrane glycoprotein involved in the enzymatic conversion of tyrosine during melanin synthesis. The tyrosinase gene encodes two distinct epitopes recognised by two different melanoma specific CTL clones. 126 127 The tyrosinase derived epitopes are also recognised by HLA-A24 restricted CTL6 135 and MHC class II restricted CD4+ Th cells. 134 The fact that the same antigen encodes both class I and II restricted epitopes would seem to enhance the interaction between CD4+ Th cells and CD8+ CTL, as recent studies suggest that the antitumour cytolytic response of CTL may be facilitated by Th cells. 136 A gene, designated MART-1, 128 or Melan-A, 130 that encodes a HLA-A2 restricted epitope on melanoma cells, was identified independently by two different groups. The function of the protein is unknown, but it seems to be a tissue differentiation antigen expressed in melanocytes, the retina and most melanomas. This epitope is particularly important because it is recognised by anti-melanoma CTL lines from 11 of 12 different patients. 139 An epitope derived from gp100 129 132 was identified by a HLA-A2 restricted CTL line generated from a patient with melanoma who was treated successfully with adoptive immunotherapy using TIL. Furthermore, gp100 was recognised by CTL lines from other patients with melanoma who had responded to TIL therapy. Another gene that has recently been shown to code for a melanoma antigen is gp75, also known as tyrosinase related protein (TRP-1). 131 Gp75, which was originally identified as an antigen recognised by serum IgG antibodies in a patient with melanoma, 136 137 is an enzyme involved in melanin synthesis and therefore expressed in human melanocytic cells and most melanomas. The presence of CTL and IgG antibodies directed against gp75 in some patients with melanoma suggests that both the cellular and humoral arms of the immune response have been activated in vivo.

All the above antigenic epitopes are presented to T cells by MHC molecules; however, non-MHC restricted tumour specific CTL have been generated against mucin molecules in human breast and pancreatic carcinomas. 139 140 The tumour associated mucins consist of underglycosylated repeating subunits that are immunogenic and presented to CTL without the need for HLA molecules.

The MAGE antigens are probably developmental antigens reexpressed during the process of carcinogenesis. Unfortunately, only about

---

**Table 2  Tumour associated antigenic epitopes in human malignancies**

<table>
<thead>
<tr>
<th>Antigen</th>
<th>MHC restriction</th>
<th>Antigenic peptide/structure</th>
<th>Distribution in normal tissue</th>
<th>Source of CTL</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAGE-1</td>
<td>A1/Cw10</td>
<td>EADPTGHSY</td>
<td>Testes</td>
<td>PBL</td>
</tr>
<tr>
<td>MAGE-3</td>
<td>A1</td>
<td>SAVGIPIKR</td>
<td>Testes</td>
<td>PBL</td>
</tr>
<tr>
<td>Tyrosinase</td>
<td>A2/A24</td>
<td>MLAVLAVCL</td>
<td>Melanocytes</td>
<td>TIL and PBL</td>
</tr>
<tr>
<td>gp100/pMel-17</td>
<td>A2/DRA4</td>
<td>YNGTMDSQV</td>
<td>Melanocytes</td>
<td>TIL</td>
</tr>
<tr>
<td>MART-1/Melan-A</td>
<td>A2/CW6</td>
<td>LLGDTQAXLRL</td>
<td>Melanocytes</td>
<td>TIL</td>
</tr>
<tr>
<td>gp75/TRP-1</td>
<td>A2/CW16</td>
<td>AAGGIGTV</td>
<td>Melanocytes</td>
<td>TIL and PBL</td>
</tr>
<tr>
<td>BAGE</td>
<td>A2</td>
<td>YLEPGPSTA</td>
<td>Melanocytes</td>
<td>TIL</td>
</tr>
<tr>
<td>GAGE</td>
<td>A2</td>
<td>MAGE-1</td>
<td>Melanocytes</td>
<td>TIL</td>
</tr>
<tr>
<td>MUC-1</td>
<td>None</td>
<td>Underglycosylated mucin</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Tumour infiltrating lymphocytes

10% of patients with melanoma develop MAGE reactive T cells as only 40% of melanomas express MAGE-1 and 25% of the population in general carry the HLA-A1 allele. This suggests that vaccinating against peptides encoded by MAGE-1 is only effective in a small and selected group of patients with melanoma. In contrast, the other antigens (tyrosinase, gp100, gp75, and MART-1) represent differentiation antigens specific to normal melanocytes and melanomas. The identification of these antigens has potential therapeutic applications. They may serve as useful targets for generating tumour specific CTL for adoptive immunotherapy and also for developing tumour vaccine. However, because these differentiation antigens are also expressed in normal melanocytes, the enhancement of immune responses against such antigens runs the risk of inducing autoimmunity and damage to normal tissue. Current efforts are directed at identifying tumour antigens that possess greater immunogenicity and specificity for the purpose of generating more effective vaccines.

Clinical trials of adoptive immunotherapy

The success of adoptive immunotherapy in murine tumour models together with the development of culture techniques that permitted large scale expansion of TIL, provided the rationale for initiating this form of therapy in clinical trials. The first phase I study with TIL administered in conjunction with IL-2 and cyclophosphamide resulted in a 55% response rate in 20 patients with metastatic melanoma. However, when this trial concluded with a total of 86 patients the response rate was reduced to 34%. A similar therapeutic response was achieved by another group without the concomitant administration of cyclophosphamide. The duration of therapeutic response ranged from two to 14 months. Mild side effects attributed to IL-2 were seen in some patients but no notable adverse effects were reported. However, subsequent studies failed to achieve any significant increase in objective response rate over treatment with IL-2 alone. A more recent phase I trial utilising repeated TIL infusion did not produce any objective response in nine patients with metastatic melanoma. Overall, the results of clinical studies conducted so far have not shown significant improvement over other immunotherapeutic modalities.

A number of factors may explain the lack of therapeutic efficacy seen in these clinical trials. It often takes several weeks of in vitro culture to expand TIL to therapeutic numbers (10^9 to 10^10). Some patients, therefore, might have untreated disease progression before treatment can be initiated. One of the main problems with TIL therapy concerns the heterogeneity and non-specific cytotoxicity of cell populations in individual TIL preparations. Perhaps the use of homogenous populations of cytotoxic TIL generated from stimulation with tumour specific peptides is one way of improving the therapeutic efficacy of TIL therapy. Furthermore, the culture conditions used for expanding TIL may be selecting the outgrowth of non-specific T cells and a better definition of growth requirements for tumour specific effectors is needed. More recent studies suggest that the change in tumour phenotype that accompanies disease progression, as demonstrated by differences in TCR expression between primary and metastatic tumours and loss of MHC class I expression, may explain the lack of efficacy in adoptive TIL therapy.

Finally, there is a problem in TIL delivery to tumour sites. Most clinical studies of TIL therapy have administered large numbers of TIL into the peripheral circulation in the hope that some of them will home to tumour deposits. As mentioned above, specific adhesion molecules regulate the migration of lymphocytes from the circulation into tumour tissue and the expression of these molecules may be lost during TIL culture and expansion. Furthermore, we have shown that cultured TIL express functionally activated integrins that are likely to promote their adhesion to low flow vascular beds, such as the liver, spleen and lungs. Clinical studies have confirmed the inefficiency of TIL delivery. A study of patients with melanoma who had received Indium-111 labelled TIL confirmed that TIL localise to tumour sites but also showed that the vast majority of infused cells become trapped in the lungs, spleen and liver. It is possible that manipulation of the culture conditions for TIL expansion will result in the development of TIL that retain their in vivo homing potential and are therefore more efficiently localised to tumour sites when infused into patients. Table 3 summarises these results.

Future directions in TIL development

There is considerable evidence that a specific anti-tumour immune response exists in many murine and human tumours. In the past, studies of human anti-tumour immunity have concentrated on CD8+ T cell activities, but recent animal studies have demonstrated that optimal host immune responses require both CD4+ and CD8+ T cell subsets. It is unclear whether each can act independently as anti-tumour effectors or as both subsets have been shown to mediate specific tumoricidal activity. A greater understanding of their interaction might enhance the generation of effector cells.

Better definition of growth requirements is necessary for selecting the expansion of specific subpopulations of TIL for functional characterisation so that we can generate homo-
genuine populations of effector cells with specific anti-tumour activity. Although a variety of cytokine combinations have been used to enhance the activity and expansion of T cells in culture, they are insufficient for selecting the outgrowth of tumour specific effector cells. It seems that regular stimulation by relevant antigens presented appropriately to T cells is required to maintain specific tumour cytotoxicity in long term cultures. The identification of tumour associated antigens will facilitate this process in two ways. Firstly, the development of synthetic peptides derived from tumour associated antigens may obviate the need for large quantities of tumour cells for antigenic restimulation of TIL. Secondly, these peptides could be used to generate tumour specific CTL from the peripheral blood, a more readily available source of effector cells. Furthermore, synthetic peptides generated from these antigens could be developed for use in anti-tumour vaccines. Such studies are designed to promote the in vivo development of an anti-tumour immune response and are currently being investigated in patients with cancer.

The efficacy of TIL might be improved either by more selective culture conditions or by artificially enhancing TIL function by genetic manipulation. The transduction of effector cells with relevant cytokine genes for TNF, INF-α and γ and IL-2 receptor may permit the production of TIL with enhanced effector functions for use in therapeutic trials. Similar genetic approaches are also being used to manipulate tumour cells in order to increase their immunogenicity and susceptibility to killing by effector cells. The administration of IFN-γ transduced tumour cells results in a cytokine mediated upregulation of MHC class I expression by tumour cells, thereby improving presentation of tumour associated antigens to immune cells. The use of IL-2 transduced tumour cells leads to a high local concentration of IL-2, which enhances TIL activation and effector functions. Already, the use of cytokine transduced tumour vaccines has been effective in animal models and phase I clinical trials are in progress.

The mechanisms of tumour derived immunosuppression need to be understood more clearly. If the tumour derived factors were known, strategies to inhibit their release could be designed, thereby enhancing TIL activation and efficacy. Although high concentrations of IL-2 can overcome the functional deficiencies of fresh TIL from human tumours, the end result of long term culture often leads to the generation of effector populations with non-specific anti-tumour cytotoxicity. A greater understanding of the ways in which tumours subvert the mechanisms of T cell signalling will facilitate the development of the next generation of cancer immunotherapies.

K F Yoong is supported by a research fellowship from BUPA/Royal College of Surgeons of England.


Tumour infiltrating lymphocytes

57 Mukherji

49 Yoong

51 Whiteside

Whiteside

B, T, JR, despite tumours.

Evidence solid specific glioblastomas.

subpopulations and the independent analysis of T-cell dependent cytokine release.

1986;90:221-33.

1995;41:42-8

http://mp.bmj.com/ Clin Mol Pathol: first published as 10.1136/mp.49.5.M256 on 1 October 1996. Downloaded from http://nrp.bmj.com/ on May 10, 2022 by guest. Protected by copyright.


Tumour infiltrating lymphocytes

...neima recognise an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. *Cancer Res* 1991;51:2908-16.


